APA (7th ed.) Citation

Emdal, K. B., Palacio-Escat, N., Wigerup, C., Eguchi, A., Nilsson, H., Bekker-Jensen, D. B., . . . Olsen, J. V. (2022). Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance. Cell reports, 40(6), . https://doi.org/10.1016/j.celrep.2022.111177

Chicago Style (17th ed.) Citation

Emdal, Kristina B., et al. "Phosphoproteomics of Primary AML Patient Samples Reveals Rationale for AKT Combination Therapy and P53 Context to Overcome Selinexor Resistance." Cell Reports 40, no. 6 (2022). https://doi.org/10.1016/j.celrep.2022.111177.

MLA (9th ed.) Citation

Emdal, Kristina B., et al. "Phosphoproteomics of Primary AML Patient Samples Reveals Rationale for AKT Combination Therapy and P53 Context to Overcome Selinexor Resistance." Cell Reports, vol. 40, no. 6, 2022, https://doi.org/10.1016/j.celrep.2022.111177.